- Home
- ACIU vs EPSN Comparison
ACIU vs EPSN Comparison
Compare ACIU & EPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- EPSN
- Stock Information
- Founded
- ACIU 2003
- EPSN 2005
- Country
- ACIU Switzerland
- EPSN Canada
- Employees
- ACIU N/A
- EPSN N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- EPSN Oil & Gas Production
- Sector
- ACIU Health Care
- EPSN Energy
- Exchange
- ACIU Nasdaq
- EPSN Nasdaq
- Market Cap
- ACIU 168.7M
- EPSN 155.9M
- IPO Year
- ACIU 2016
- EPSN N/A
- Fundamental
- Price
- ACIU $1.73
- EPSN $7.20
- Analyst Decision
- ACIU Strong Buy
- EPSN Strong Buy
- Analyst Count
- ACIU 2
- EPSN 1
- Target Price
- ACIU $10.00
- EPSN $7.00
- AVG Volume (30 Days)
- ACIU 103.2K
- EPSN 92.3K
- Earning Date
- ACIU 08-05-2025
- EPSN 05-14-2025
- Dividend Yield
- ACIU N/A
- EPSN 3.43%
- EPS Growth
- ACIU N/A
- EPSN N/A
- EPS
- ACIU N/A
- EPSN 0.20
- Revenue
- ACIU $32,014,254.00
- EPSN $39,699,172.00
- Revenue This Year
- ACIU N/A
- EPSN $41.35
- Revenue Next Year
- ACIU $533.21
- EPSN N/A
- P/E Ratio
- ACIU N/A
- EPSN $35.77
- Revenue Growth
- ACIU 91.20
- EPSN 35.21
- 52 Week Low
- ACIU $1.43
- EPSN $4.95
- 52 Week High
- ACIU $4.98
- EPSN $7.59
- Technical
- Relative Strength Index (RSI)
- ACIU 54.55
- EPSN 56.19
- Support Level
- ACIU $1.60
- EPSN $6.91
- Resistance Level
- ACIU $1.82
- EPSN $7.59
- Average True Range (ATR)
- ACIU 0.10
- EPSN 0.26
- MACD
- ACIU 0.01
- EPSN 0.01
- Stochastic Oscillator
- ACIU 65.38
- EPSN 44.29
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.